Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Frontiers in Immunology · September 10, 2026
Raises a question worth testing. It does not answer one.
This narrative review proposes that immune checkpoint pathways, validated in cancer immunotherapy, may be therapeutically harnessed in autoimmune disease through agonism rather than blockade to restore immune tolerance. The authors identify conceptual promise (exemplified by abatacept and emerging PD-1 agonists) but acknowledge substantial mechanistic uncertainty, lack of predictive biomarkers, and a translational gap between transplant models and chronic autoimmunity.
Journal article. Patients with autoimmune diseases; discussion also encompasses cancer immunotherapy and transplant models for mechanistic contrast.
CTLA-4-Ig (abatacept) demonstrates clinical success in autoimmune disease via IC agonism PD-1 agonists (e.g., peresolimab) show emerging efficacy as proof-of-concept for augmenting inhibitory signaling Immune checkpoint function in autoimmune disease acts as inhibitory receptors fine-tuning autoreactive cells rather than inducing classical T-cell exhaustion
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should recognize that immune checkpoint modulation in autoimmunity differs fundamentally from oncology (agonism vs. blockade), and that current therapies (abatacept, emerging PD-1 agonists) provide proof-of-concept but lack mechanistic predictability and biomarker-guided patient selection. Further biomarker-driven development and multi-omics profiling are required before broad adoption.
This is a narrative review synthesizing mechanistic concepts and early clinical observations rather than reporting original experimental or clinical trial data with defined endpoints and effect sizes.
Clinicians and researchers should recognize that immune checkpoint modulation in autoimmunity differs fundamentally from oncology (agonism vs. blockade), and that current therapies (abatacept, emerging PD-1 agonists) provide proof-of-concept but lack mechanistic predictability and biomarker-guided patient selection. Further biomarker-driven development and multi-omics profiling are required before broad adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint (IC) pathways, originally identified in T-cell exhaustion in cancer, are increasingly recognized as key modulators of immune tolerance in autoimmune diseases (ADs). In ADs, these molecules function more accurately as inhibitory receptors (IRs) that fine-tune, rather than inducing classical exhaustion phenotypes, autoreactive immune cells. Unlike oncology, where checkpoint blockade enhances immunity, AD therapy aims to restore tolerance through IC agonism or immune reset approaches (e.g., CAR-T cells). This review synthesizes recent advances in targeting CTLA-4, PD-1, LAG-3, TIM-3, and TIGIT. Clinical success with CTLA-4-Ig (abatacept) and emerging efficacy of PD-1 agonists (e.g., peresolimab) provide proof-of-concept that augmenting inhibitory signaling can ameliorate autoimmunity. However, outcomes remain context-dependent, reflecting interplay between effector and regulatory subsets and tissue-specific environments. Mechanistic challenges, including multivalent receptor engagement, ligand complexity, and signaling heterogeneity (e.g., ITIM/ITSM phosphorylation), limit current approaches. Insights from immune-related adverse events (irAEs) highlight shared pathways of dysregulation and inform risk-benefit considerations. A major translational gap persists between acute transplant models and chronic autoimmunity, and validated predictive biomarkers are lacking. Beyond T cells, B cells, dendritic cells, and innate populations expand therapeutic opportunities. Future progress will require multi-omics profiling, biomarker-driven stratification, and next-generation agonist design. IC-targeted strategies hold promises but demand context-aware, mechanistically informed development for broad clinical impact in ADs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.